Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen

NCT00129961 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00129961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00129961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2005
Completion date
January 31, 2009
Enrollment
86 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation, skin neoplasms